Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1487320 | 1.00 | ALDH1A1 (0.39) | ALDH1A1CYP3A4MAPTCYP2D6 | |
| Hydrochloric Acid SCHEMBL4207271 | 1.00 | ALDH1A1 (0.39) | ALDH1A1CYP3A4MAPTCYP2D6 | |
| SCHEMBL3864537 | 0.98 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MAPTCYP2D6 | |
| SCHEMBL3864539 | 0.98 | ALDH1A1 (0.36) | ALDH1A1CYP3A4MAPTCYP2D6 | |
| Water SCHEMBL30525491 | 0.96 | ALDH1A1 (0.34) | ALDH1A1CYP3A4MAPTCYP2D6 | |
| Water SCHEMBL31024411 | 0.96 | ALDH1A1 (0.34) | ALDH1A1CYP3A4MAPTCYP2D6 | |
| Hydrochloric Acid SCHEMBL10782209 | 0.83 | ALDH1A1 (0.39) | ALDH1A1CYP3A4MAPTCYP2D6 | |
| Hydrochloric Acid SCHEMBL10782216 | 0.83 | ALDH1A1 (0.39) | ALDH1A1CYP3A4MAPTCYP2D6 | |
| SCHEMBL5354801 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL10784283 | 0.79 | GRIN2D (0.37) | ALDH1A1CYP3A4MAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3569634-B1 | CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME | XEROX CORP (US) | 2023-04-19 | — | — | EP | claimed |
| US-10703859-B2 | Compositions comprising unsaturated crystalline polyester for 3D printing | XEROX CORPORATION (US) | 2020-07-07 | — | — | US | claimed |
| US-10655025-B2 | Curable unsaturated crystalline polyester powder and methods of making the same | XEROX CORPORATION (US) | 2020-05-19 | — | — | US | claimed |
| US-20190352455-A1 | COMPOSITIONS COMPRISING UNSATURATED CRYSTALLINE POLYESTER FOR 3D PRINTING | Genesee Valley Innovations, LLC | 2019-11-21 | — | — | US | claimed |
| US-20190352521-A1 | CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME | Genesee Valley Innovations, LLC | 2019-11-21 | — | — | US | claimed |
| EP-3569634-A1 | CURABLE UNSATURATED CRYSTALLINE POLYESTER POWDER AND METHODS OF MAKING THE SAME | Xerox Corporation (US) | 2019-11-20 | — | — | EP | claimed |
| EP-3569633-A1 | COMPOSITIONS COMPRISING UNSATURATED CRYSTALLINE POLYESTER FOR 3D PRINTING | Xerox Corporation (US) | 2019-11-20 | — | — | EP | claimed |
| US-20070298336-A1 | Carrier coating | XEROX CORPORATION (US) | 2007-12-27 | — | — | US | claimed |
| EP-0767212-B1 | PROCESS FOR PRODUCING AN AQUEOUS SOLUTION OF PHOSPHORYLCHOLINE GROUP BEARING POLYMER AND AQUEOUS SOLUTION OF PHOSPHORYLCHOLINE GROUP BEARING POLYMER | NOF CORP (JP) | 2001-07-18 | — | — | EP | claimed |
| US-6204324-B1 | AN ETHYLENICALLY UNSATURATED POLYMERIZABLE MONOMER HAVING THE PHOSPHORYLCHOLINE GROUP IS POLYMERIZED IN THE PRESENCE OF A NON-METAL POLYMERIZATION INITIATOR SOLUTION CONTAINING PEROXY OR AZO COMPOUNDS | NOF CORPORATION (JP) | 2001-03-20 | — | — | US | claimed |
| US-6136490-A | SUSPENSION POLYMERIZING A MONOMER OR A MIXTURE OF TWO OR MOREMONOMERS FOR A CORE AND SUSPENSION POLYMERIZING A MONOMER OR MIXTURE OR TWO OR MORE MONOMERS FOR SHELL IN DISPERSION MEDIA USING A DIAZO COMPOUND AS POLYMERIZATION INITIATOR | NIPPON ZEON CO., LTD. (JP) | 2000-10-24 | — | — | US | claimed |
| EP-0767212-A1 | PROCESS FOR PRODUCING AN AQUEOUS SOLUTION OF PHOSPHORYLCHOLINE GROUP BEARING POLYMER AND AQUEOUS SOLUTION OF PHOSPHORYLCHOLINE GROUP BEARING POLYMER | Japan Science and Technology Corporation (JP) | 1997-04-09 | — | — | EP | claimed |
| US-12577432-B2 | Organosilicon compound, production method therefor, and curable composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-4282653-B1 | ORGANOSILICON COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE COMPOSITION | SHINETSU CHEMICAL CO (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-12522684-B2 | Active-energy-ray-curable resin composition and cured product thereof | NIPPON SHOKUBAI CO., LTD. (JP) | 2026-01-13 | — | — | US | disclosed |
| EP-4001367-B1 | AQUEOUS INKJET INK COMPOSITIONS MADE FROM HIGH VISCOSITY LATEXES | XEROX CORP (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-1992017635-A1 | ISOCYANATE DERIVATIVES COMPRISING FLUOROCHEMICAL OLIGOMERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-10-15 | — | — | WO | disclosed |
| US-4644042-A | USING WATER SOLUBLE FREE RADICAL POLYMERIZATION CATALYST | NITTO BOSEKI CO., LTD. (JP) | 1987-02-17 | — | — | US | disclosed |
| EP-0196588-A2 | Process for the preparation of copolymers of N-substituted secondary monoallylamines or salts thereof | NITTO BOSEKI CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| EP-0173963-A2 | Polymers of n-substituted secondary monoallylamines and their salts and process for producing the same | NITTO BOSEKI CO., LTD. (JP) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577432-B2 | Organosilicon compound, production method therefor, and curable composition | ASH2L, DOT1L, DNMT3L | ALDH1A1 726/4885CYP3A4 423/4885MAPT 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.